- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03698045
Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. (PRO-143)
Study to Evaluate the Safety and Tolerability of Pro-143 Ophthalmic Solution in Healthy Volunteers.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Jalisco
-
Guadalajara, Jalisco, Mexique, 44100
- Independent Clinical Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy male and female.
- Age ≥ 18 years old at screening visit.
Exclusion Criteria:
- Any ocular or systemic condition.
- Patient with one blind eye.
- Visual acuity of 20/40 in any eye.
- Use of ocular or systemics medications.
- Contraindications or sensitivity to any component of the study treatments.
- Contact lens users.
- Ocular surgery within the past 3 months..
- Women who were not using an effective means of contraception or who were pregnant or nursing.
- Participation in any studies of investigational drugs within 90 days previous to the inclusion.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PRO-143 Ophthalmic Solution
PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
|
PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Conjunctival bulbar hyperemia
Délai: 10 days
|
Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity. He will graduate using the Efron scale. 0 Normal , 1 Very slight, 2 Mild, 3 Moderate, 4 Severe. |
10 days
|
|
Number of Participants with adverse events
Délai: 10 days
|
he evaluation of adverse events requires a questioning conducted by the principal investigator and the appropriate exploratory techniques for its detection.
the number of adverse events per study group will be considered for the analysis
|
10 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Intraocular pressure (IOP)
Délai: 10 days
|
Tonometry is the objective measure of Intraocular pressure, based primarily on the force required to flatten the cornea, or the degree of corneal indentation produced by a fixed force.
Goldman's tonometry is based on the Imbert-Fick principle.
the result will be expressed in millimeters of mercury and the comparison between groups will be carried out.
|
10 days
|
|
Visual ability (VA)
Délai: 10 days
|
The VA will be evaluated basally, without refractive correction with the Snellen chart.
Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated
|
10 days
|
|
Eye comfort index (ICO)
Délai: 10 days
|
It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100). Similar to the index for ocular surface diseases, the ocular comfort index (ICO) evaluates symptoms. The ICO contains 6 items that focus on the discomfort associated with the ocular surface. Each of these questions has two parts, which inquire separately the frequency and severity of the symptoms. The evaluator will deliver the questionnaire to the subject and allow the subject to answer it calmly without any pressure and / or coercion, will only assist him if he has difficulty understanding any of the questions. |
10 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Leopoldo M Baiza-Durán, MD, Clinical Research Department. Laboratorios Sophia SA de CV
- Chercheur principal: José F Alaniz-De La O, MD, Independent Clinical Research Center
- Chercheur principal: Laura R Saucedo-Rodíguez, MD, Independent Clinical Research Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SOPH143-0212/I
- PRO-143
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .